Locally advanced breast cancer
Conditions
Interventions
1:Cisplatin plus gemcitabine
2:Vinorelbine bitartrate plus Cisplatin
3:TAC
Sponsors
Affliated Tumor Hospital of Xinjiang Medical University
Eligibility
Sex/Gender
Female
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1) Nonpregnant female aged 18-70 years; 2) Physical score between 1-2 according to Eastern Cancer Cooperative Group(ECOG); 3) Inoperable or locally advanced beast cancer patients(non-inflammatory breast cancer,including phase IIB,IIIA,IIIB) confirmed by auxiliary inspections(pathology and CT,etc); 4) At least 1 measurable lesion(lesion diameter=20mm by CT or MRI,lesion diameter=10mm by spiral CT); 5) Without dysfunctions of major organs(with normal blood routine, liver function, renal function, heart function,electrolyte); WBC=4.0×10^9/L, N=1.5×10^9/L,PLT=100×10^9/L, HGB=95g/L, serum bilirubin=1.5 times normal upper limit, ALT & AST=2 times normal upper limit, serum creatinine =1.5mg/dl; with nornal result of chest film, abdominal B ultrasound, contralateral mammography,bone scan; 6) Have the ability of understanding this study and signing informed consent; 7) Efficacy evaluated as SD after 2 cycles of TAC neoadjuvant chemotherapy.
Exclusion criteria
Exclusion criteria: 1) Her-2 (3+) or FISH (+); 2) Allergic to all of the chemotherapy drugs before; 3) Currently receiving other anticancer treatment; 4) Without measurable lesions; 5) Others, including any situation of the following: with uncontrolled central nervous system metastases; with major organ dyfunction and severe heart disease including congestive heart failure, uncontrollable arrhythmia, angina requiring long-term medical treatment, heart valve disease,myocardial infarction and refractory hypertension; pregnant or breast-feeding women; with protracted infectious wound; with past history of mental illness which is not easy to control.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| pCR; | — |
Countries
China
Contacts
Public ContactBinlin Ma, Xun Li
Affliated Tumor Hospital of Xinjiang Medical University
Outcome results
None listed